Top Ten most popular articles on this week

pharmafile | June 8, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical 

With ASCO occurring over the weekend, the headlines this week have been dominated by the news of breaking research that will be talked about more in the weeks and months to come.

Our article with the most views focuses on the decision to award the EMA headquarters to Amsterdam, in a decision-making process that was widely discussed as having seemed a little chaotic. Milan is now voicing exactly why it was left so displeased by the process.

Check out the week’s ten most popular articles on now!

10. Amgen/Novartis migraine med gets CHMP nod

Amgen and Novartis have announced that their newly FDA-approved treatment for migraines has received a recommendation from the CHMP, generally a precursor to an approval by the EMA.

9. Keytruda offers significant hope in subset of prostate cancer

A team from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust were able to use MSD’s Keytruda to good effect in 38% of men.

8. J&J looks to trim business with $2.8bn sale

Johnson & Johnson continues to look at options to slim down its business, after having received an offer from Fortive to sell its medical-sterilisation unit for $2.8 billion.

7. NICE recommends MSD’s Keytruda for advanced PD-L1-positive lung cancer

NICE has chosen to issue final guidance recommending the use of MSD’s Keytruda on the NHS for the treatment of previously untreated PD-L1-positive metastatic non-small-cell lung cancer in adult patients.

6. Pfizer pumps $600m into venture fund, targeting neuroscience

Pfizer’s move to dump its neuroscience divisions caused serious ripples through the industry, but it’s now back although in a different guise.

5. Janssen debuts promising new cancer data at ASCO

Janssen took the opportunity at ASCO to present promising new Phase 2 and 3 data on two of its candidates: erdafitinib in metastatic urothelial cancer, and Imbruvica combined with rituximab in the treatment of Waldenström’s Macroglobulinemia.

4. Allergan mauled by investors in public letter

Douglas Silverman, Managing Partner at Senator Investment Group, and David Tepper, CEO of Appaloosa, penned an open letter stating, in no uncertain terms, how “underwhelmed” they were with the stategic review that Allergan announced last week.

3. Roche’s breast, lung cancer offerings fail to impress at ASCO

Roche made an underwhelming impact at the American Society of Clinical Oncology annual event in Chicago, after revealing data which demonstrated only mediocre efficacy for two of its therapies for breast and lung cancer.

2. Mylan lands biosimilar sucker punch to Amgen’s blockbuster

Mylan and Biocon have received FDA approval for their biosimilar to Amgen’s Neulasta, setting the companies on track to snatch a chunk of the treatment’s $4.2 billion per year in sales, as recorded last year.

1. Milan’s decision to appeal the EMA HQ relocation explained

The decision to award the EMA headquarters to Amsterdam was a contentious one, and now Diana Bracco, CEO of the Bracco Group, part of Milan campaign group, explains why the city is appealing the decision.

Related Content

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

India report record number of COVID deaths as bodies drift down Ganges

India yesterday reported the country’s highest COVID-19 death total for a single day, with 4,205 …

Latest content